Beta Bionics, Inc. (BBNX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 32/100 (MEDIUM), 28.2 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 23.83% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Beta Bionics (BBNX) Stock Fair Value Rises After Mint Clearance And Analyst Target Changes
- Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal
- Beta Bionics to Announce Third Quarter 2026 Financial Results on October 27, 2026
- Beta Bionics Announces Agreement Integrate the iLet® Bionic Pancreas and mint™ with Senseonics’ Eversense® 365
- Beta Bionics Announces Closing of $172.5 Million Public Offering of Common Stock
- Beta Bionics, Inc. (BBNX) Surges 15.3%: Is This an Indication of Further Gains?
- Beta Bionics (BBNX) Stock Sees Fair Value Lift As Analysts Reassess Pipeline Timing
- Beta Bionics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Beta Bionics, Inc..
Full BBNX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.